Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Oncogene – Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Related Articles
The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Maurice PĂ©rol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
Apolipoprotein B-containing lipoproteins in atherogenesis
Nature Reviews Cardiology – In this Review, BorĂ©n and colleagues present insights into the role of apolipoprotein B-containing lipoproteins in atherogenesis, with an emphasis on…
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Nature Medicine – Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected…
Precision-guided treatment in high-risk pediatric cancers
Nature Medicine – In the observational ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial, children with high-risk cancer were…
Benefits for children with suspected cancer from routine whole-genome sequencing
Nature Medicine – In a cohort of 281 children with diagnosed or suspected cancer presenting to the NHS, implementing routine whole-genome sequencing provided clinical benefit…
DLL3 Inhibitor Licensed to Roche
Innovent Biologics will license IBI3009, its investigational DLL3-targeted antibody–drug conjugate (ADC) for small cell lung cancer (SCLC), to Roche for $80 million upfront and payments…
Multiple Myeloma Patients Report Persistent Pain and Opioid Use During Remission
Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests.
